^
    Back
    Association details:
    Biomarker:KLHL31-LRRC1-ALK fusion
    Cancer:Lung Adenocarcinoma
    Drug:Ensacove (ensartinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Thorac Oncol
    Title:

    A Novel Intergenic Region Between KLHL31 and LRRC1-ALK Exon 20 Fusion Variant in Advanced Lung Adenocarcinoma and its Remarkable Response to ALK Inhibitor

    Published date:
    04/01/2021
    Excerpt:
    ...we report a novel intergenic region between KLHL31 and LRRC1-ALK fusion variant in a patient with lung adenocarcinoma and its remarkable response to ensartinib.
    DOI:
    https://doi.org/10.1016/j.jtho.2020.12.016